

MARICO LIMITED					
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025					
					Rs. in crore
Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2025 (Unaudited)	March 31, 2025 (Audited) (Refer note 6)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1	Revenue from operations	3,259	2,730	2,643	10,831
2	Other income	56	47	37	208
3	<b>Total income (1 + 2)</b>	<b>3,315</b>	<b>2,777</b>	<b>2,680</b>	<b>11,039</b>
4	<b>Expenses</b>				
	(a) Cost of materials consumed	1,184	1,033	1,107	4,572
	(b) Purchase of stock-in-trade	317	252	207	960
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	229	119	(52)	(144)
	(d) Employee benefits expense	220	208	203	831
	(e) Finance cost	10	12	17	53
	(f) Depreciation and amortisation expense	45	52	41	178
	(g) Other expenses				
	Advertisement and sales promotion	299	305	240	1,128
	Others	355	355	312	1,345
	<b>Total expenses</b>	<b>2,659</b>	<b>2,336</b>	<b>2,075</b>	<b>8,923</b>
5	<b>Profit before tax (3 - 4)</b>	<b>656</b>	<b>441</b>	<b>605</b>	<b>2,116</b>
6	<b>Tax expense</b>				
	Current tax	157	99	135	480
	Deferred tax charge / (credit)	(14)	(3)	(4)	(22)
	<b>Tax expense for the period</b>	<b>143</b>	<b>96</b>	<b>131</b>	<b>458</b>
7	<b>Net profit for the period (5 - 6)</b>	<b>513</b>	<b>345</b>	<b>474</b>	<b>1,658</b>
8	<b>Other comprehensive income / (loss)</b>				
	A. (i) Items that will not be reclassified to profit or loss				
	Remeasurements of post employment benefit obligations	0	(0)	0	(1)
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	Remeasurements of post employment benefit obligations	0	(0)	-	0
	B. (i) Items that will be reclassified to profit or loss				
	Exchange differences on translation of foreign operations	(13)	(16)	(59)	(75)
	Change in fair value of hedging instruments	(1)	2	0	1
	(ii) Income tax relating to items that will be reclassified to profit or loss				
	Change in fair value of hedging instruments	(0)	(1)	0	(0)
	<b>Other comprehensive income / (loss)</b>	<b>(14)</b>	<b>(15)</b>	<b>(59)</b>	<b>(74)</b>
9	<b>Total comprehensive income for the period (7+8)</b>	<b>499</b>	<b>330</b>	<b>415</b>	<b>1,584</b>
10	Net profit attributable to:				
	- Owners	504	343	464	1,629
	- Non-controlling interests	9	2	10	29
11	Other comprehensive income / (loss) attributable to:				
	- Owners	(14)	(14)	(54)	(69)
	- Non-controlling interests	0	(1)	(5)	(5)
12	Total comprehensive income attributable to:				
	- Owners	490	329	410	1,560
	- Non-controlling interests	9	1	5	24
13	Paid-up equity share capital (Face value of Re. 1/- per share)	129	129	129	129
14	Other equity				3,846
15	Earnings per share (of Re. 1 /- each) ( Not annualised)				
	(a) Basic (in Rs.)	3.90	2.65	3.60	12.59
	(b) Diluted (in Rs.)	3.89	2.65	3.59	12.56
	See accompanying notes to the financial results				

#### Notes to the Marico Limited Consolidated financial results:

1. The Consolidated unaudited financial results for the quarter ended June 30, 2025 (“the statement”) were reviewed by the Audit Committee and approved by the Board of Directors of Marico Limited ("the Company") at their meeting held on August 4, 2025 and are available on the Company’s website - <http://www.marico.com> and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)). These results have been subjected to limited review by the statutory auditors.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Consolidated financial results for the quarter ended June 30, 2025, comprise results of Marico Limited, its subsidiaries and step-down subsidiaries in India, Bangladesh, UAE, Egypt, South Africa, Malaysia, Sri Lanka, Vietnam and USA. All the aforesaid entities are collectively called 'Marico'.
4. During the quarter ended June 30, 2025, the Company acquired 8.8% stake in Satiya Nutraceuticals Private Limited (“Plix”) on a fully diluted basis from the existing investors. Consequently, the Company’s stake in Plix now stands at 60% on a fully diluted basis.

5. In accordance with the Indian Accounting Standard - Ind AS 108, the Company has organized the business into two segments viz, India and International. Accordingly, the Company has reported its segmental results for these segments.

(Rs. in crores)

	Quarter ended			Year ended
	June 30, 2025 (Unaudited)	March 31, 2025 (Audited) (Refer note 6)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
Segment revenue (Sales and other operating income)				
India	2,495	2,068	1,962	8,110
International	764	662	681	2,721
<b>Total Segment Revenue</b>	<b>3,259</b>	<b>2,730</b>	<b>2,643</b>	<b>10,831</b>
Less : Inter segment revenue	-	-	-	-
<b>Net Segment Revenue</b>	<b>3,259</b>	<b>2,730</b>	<b>2,643</b>	<b>10,831</b>
Segment Results (Profit before tax and interest)				
India	469	322	444	1,550
International	213	159	197	711
<b>Total Segment Results</b>	<b>682</b>	<b>481</b>	<b>641</b>	<b>2,261</b>
Less :				
(i) Finance cost	10	12	17	53
(ii) Other un-allocable expenditure net of un-allocable income	16	28	19	92
<b>Profit Before Tax</b>	<b>656</b>	<b>441</b>	<b>605</b>	<b>2,116</b>
Segment Assets				
India	3,626	3,757	3,844	3,757
International	1,982	2,123	1,940	2,123
Un-allocated	3,346	2,458	1,847	2,458
<b>Total Assets</b>	<b>8,954</b>	<b>8,338</b>	<b>7,631</b>	<b>8,338</b>
Segment Liabilities				
India	1,256	1,103	1,136	1,103
International	815	949	712	949
Un-allocated	2,176	2,020	1,186	2,020
<b>Total Liabilities</b>	<b>4,247</b>	<b>4,072</b>	<b>3,034</b>	<b>4,072</b>

6. The figures for the three months ended March 31, 2025, are arrived at as difference between audited figures in respect of full financial year and the unaudited published figures upto nine months ended December 31 of the previous financial year. Also, the figures upto the end of third quarter had only been reviewed and not subjected to audit.

Place – Mumbai

Date: August 04, 2025

VIJAY

MATHUR

Digitally signed  
by VIJAY  
MATHUR

Date: 2025.08.04  
13:27:58 +05'30'

SAUGAT A GUPTA Digitally signed by  
SAUGATA GUPTA  
Date: 2025.08.04  
13:12:34 +05'30'

Saugata Gupta

Managing Director & CEO

## **About Marico:**

Marico (BSE: 531642, NSE: "MARICO") is one of India's leading consumer products companies operating in the global beauty and wellness categories. During FY24-25, Marico recorded a turnover of ₹ 108.3 billion (USD 1.3 billion) through its products sold in India and chosen markets in Asia and Africa.

Marico touches the lives of 1 out of every 3 Indians, through its portfolio of brands such as Parachute, Saffola, Hair & Care, Parachute Advansed, Nihar Naturals, Mediker, Pure Sense, Coco Soul, Revive, Set Wet, Livon, Beardo, Just Herbs, True Elements and Plix. The overseas consumer products portfolio contributes to about 25% of the Group's revenue, with brands like Parachute, Parachute Advansed, HairCode, Fiancée, Purité de Prôvence, Ôliv, Caivil, Hercules, Black Chic, Code 10, Ingwe, X-Men, Thuan Phat and Isoplus.

As part of Marico's Green Initiative, your Company wants to make its contribution to save the environment by sending its shareholders the Annual Report and other communication using the electronic medium. Therefore, Members holding shares in dematerialized form are requested to contact their respective Depository Participant to update their email address. Members holding shares in physical form can write to the RTA at [rnt.helpdesk@linkintime.co.in](mailto:rnt.helpdesk@linkintime.co.in).

Marico Limited

Reg Office: 7th floor, Grande Palladium, 175, CST Road, Kalina, Santacruz (East),

Mumbai 400 098

Tel: (91-22) 6648 0480

MARICO LIMITED

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

		Rs. in crore			
Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2025 (Unaudited)	March 31, 2025 (Audited) (Refer note 5)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1	Revenue from operations	2,281	1,870	1,886	7,581
2	Other income	474	149	18	591
3	<b>Total income (1 + 2)</b>	<b>2,755</b>	<b>2,019</b>	<b>1,904</b>	<b>8,172</b>
4	<b>Expenses</b>				
	(a) Cost of materials consumed	1,008	890	964	3,968
	(b) Purchase of stock-in-trade	123	96	88	408
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	257	116	(42)	(107)
	(d) Employee benefits expense	136	124	127	505
	(e) Finance cost	5	5	5	23
	(f) Depreciation and amortisation expense	30	38	28	123
	(g) Other expenses				
	Advertisement and sales promotion	84	98	106	434
	Others	224	234	215	924
	<b>Total expenses</b>	<b>1,867</b>	<b>1,601</b>	<b>1,491</b>	<b>6,278</b>
5	<b>Profit before tax (3 - 4)</b>	<b>888</b>	<b>418</b>	<b>413</b>	<b>1,894</b>
6	<b>Tax expense</b>				
	Current tax	119	70	88	320
	Deferred tax charge /(credit)	(8)	23	14	33
	<b>Tax expense for the period</b>	<b>111</b>	<b>93</b>	<b>102</b>	<b>353</b>
7	<b>Net profit for the period (5 - 6)</b>	<b>777</b>	<b>325</b>	<b>311</b>	<b>1,541</b>
8	<b>Other comprehensive income / (loss)</b>				
	A. (i) Items that will not be reclassified to profit or loss				
	Remeasurements of post employment benefit obligations	-	(0)	-	(0)
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	Remeasurements of post employment benefit obligations	-	0	-	0
	B. (i) Items that will be reclassified to profit or loss				
	Change in fair value of hedging instruments	(1)	2	0	1
	(ii) Income tax relating to items that will be reclassified to profit or loss				
	Change in fair value of hedging instruments	(0)	(1)	0	(0)
	<b>Other comprehensive income / (loss) , net of tax</b>	<b>(1)</b>	<b>1</b>	<b>0</b>	<b>1</b>
9	<b>Total comprehensive income for the period (7 + 8)</b>	<b>776</b>	<b>326</b>	<b>311</b>	<b>1,542</b>
10	Paid-up equity share capital (Face value of Re. 1/- per share)	129	129	129	129
11	Other equity				4,634
12	Earnings per share (of Re 1 /- each) ( Not annualised)				
	(a) Basic (in Rs.)	6.01	2.51	2.41	11.91
	(b) Diluted (in Rs.)	5.99	2.51	2.40	11.88
	See accompanying notes to the financial results				

## Notes to the Marico Limited Standalone financial results:

1. The Standalone unaudited financial results for the quarter ended June 30, 2025 ("the statement") were reviewed by the Audit Committee and approved by the Board of Directors of Marico Limited ("the Company") at their meeting held on August 4, 2025 and are available on the Company's website - <http://www.marico.com> and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)). These results have been subjected to limited review by the statutory auditors.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. In accordance with the Indian Accounting Standard - Ind AS 108, the Company has disclosed segment results in consolidated financial results.
4. During the quarter ended June 30, 2025, the Company acquired 8.8% stake in Satiya Nutraceuticals Private Limited ("Plix") on a fully diluted basis from the existing investors. Consequently, the Company's stake in Plix now stands at 60% on a fully diluted basis.
5. The figures for the three months ended March 31, 2025, are arrived at as difference between audited figures in respect of full financial year and the unaudited published figures upto nine months ended December 31 of the previous financial year. Also, the figures upto the end of third quarter have only been reviewed and not subjected to audit.

Place - Mumbai

Date: August 04, 2025

VIJAY

MATHUR

Digitally signed  
by VIJAY  
MATHUR

Date: 2025.08.04  
13:26:22 +05'30'

SAUGATA  
A GUPTA

Digitally signed by  
SAUGATA GUPTA  
Date: 2025.08.04  
13:13:11 +05'30'

Saugata Gupta

Managing Director & CEO